ELI LILLY AND COMPANY Gain (Loss) on Investments
ELI LILLY AND COMPANY (LLY) reported Gain (Loss) on Investments of -$35.30 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2025-08-07
- ELI LILLY AND COMPANY gain (loss) on investments for the quarter ending 2025-06-30 was $113.80M.
- ELI LILLY AND COMPANY gain (loss) on investments for the quarter ending 2025-03-31 was -$149.10M, a 1043.67% decline year-over-year.
- ELI LILLY AND COMPANY gain (loss) on investments for the quarter ending 2024-12-31 was -$20.00M, a 116.53% decline year-over-year.
- ELI LILLY AND COMPANY gain (loss) on investments for the quarter ending 2024-09-30 was $112.40M.
- ELI LILLY AND COMPANY gain (loss) on investments for fiscal 2024 was -$49.80M.
- ELI LILLY AND COMPANY gain (loss) on investments for fiscal 2023 was -$23.50M.
- ELI LILLY AND COMPANY gain (loss) on investments for fiscal 2022 was -$420.00M, a 335.96% decline from fiscal 2021.
- ELI LILLY AND COMPANY gain (loss) on investments for fiscal 2021 was $178.00M, a 87.63% decline from fiscal 2020.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2025-06-30 | $113.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$35.30M 10-Q · filed 2025-08-07 | -$55.30M derived: sum of 3 quarters · filed 2025-08-07 | $57.10M derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | -$149.10M 10-Q · filed 2025-05-01 | -$169.10M derived: sum of 2 quarters · filed 2025-05-01 | -$56.70M derived: sum of 3 quarters · filed 2025-05-01 | -$214.70M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-12-31 | -$20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $92.40M derived: sum of 2 quarters · filed 2025-02-19 | -$65.60M derived: sum of 3 quarters · filed 2025-08-07 | -$49.80M 10-K · filed 2025-02-19 |
| 2024-09-30 | $112.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$45.60M derived: sum of 2 quarters · filed 2025-08-07 | -$29.80M 10-Q · filed 2024-10-30 | $91.20M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-06-30 | -$158.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$142.20M 10-Q · filed 2025-08-07 | -$21.20M derived: sum of 3 quarters · filed 2025-08-07 | -$85.70M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $15.80M 10-Q · filed 2025-05-01 | $136.80M derived: sum of 2 quarters · filed 2025-05-01 | $72.30M derived: sum of 3 quarters · filed 2025-05-01 | $6.50M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $121.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $56.50M derived: sum of 2 quarters · filed 2025-02-19 | -$9.30M derived: sum of 3 quarters · filed 2025-02-19 | -$23.50M 10-K · filed 2025-02-19 |
| 2023-09-30 | -$64.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$130.30M derived: sum of 2 quarters · filed 2024-10-30 | -$144.50M 10-Q · filed 2024-10-30 | $111.90M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | -$65.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$80.00M 10-Q · filed 2024-08-08 | $176.40M derived: sum of 3 quarters · filed 2025-02-19 | $45.60M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | -$14.20M 10-Q · filed 2024-04-30 | $242.20M derived: sum of 2 quarters · filed 2025-02-19 | $111.40M derived: sum of 3 quarters · filed 2025-02-19 | -$8.10M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $256.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $125.60M derived: sum of 2 quarters · filed 2025-02-19 | $6.10M derived: sum of 3 quarters · filed 2025-02-19 | -$420.00M 10-K · filed 2025-02-19 |
| 2022-09-30 | -$130.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$250.30M derived: sum of 2 quarters · filed 2023-11-02 | -$676.40M 10-Q · filed 2023-11-02 | -$769.50M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$119.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$545.60M 10-Q · filed 2023-08-08 | -$638.70M derived: sum of 3 quarters · filed 2024-02-21 | -$885.70M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$426.10M 10-Q · filed 2023-04-27 | -$519.20M derived: sum of 2 quarters · filed 2024-02-21 | -$766.20M derived: sum of 3 quarters · filed 2024-02-21 | -$550.30M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | -$93.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$340.10M derived: sum of 2 quarters · filed 2024-02-21 | -$124.20M derived: sum of 3 quarters · filed 2024-02-21 | $178.00M 10-K · filed 2024-02-21 |
| 2021-09-30 | -$247.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$31.10M derived: sum of 2 quarters · filed 2022-11-01 | $271.10M 10-Q · filed 2022-11-01 | $800.10M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $215.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $518.10M 10-Q · filed 2022-08-04 | $1.05B derived: sum of 3 quarters · filed 2023-02-22 | $1.19B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $302.20M 10-Q · filed 2022-04-29 | $831.20M derived: sum of 2 quarters · filed 2023-02-22 | $975.70M derived: sum of 3 quarters · filed 2023-02-22 | $1.55B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $529.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $673.50M derived: sum of 2 quarters · filed 2023-02-22 | $1.25B derived: sum of 3 quarters · filed 2023-02-22 | $1.44B 10-K · filed 2023-02-22 |
| 2020-09-30 | $144.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $722.80M derived: sum of 2 quarters · filed 2021-10-27 | $909.50M 10-Q · filed 2021-10-27 | $1.14B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $578.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $765.00M 10-Q · filed 2021-08-03 | $990.50M derived: sum of 3 quarters · filed 2022-02-23 | $1.04B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $186.70M 10-Q · filed 2021-04-30 | $412.20M derived: sum of 2 quarters · filed 2022-02-23 | $462.30M derived: sum of 3 quarters · filed 2022-02-23 | |
| 2019-12-31 | $225.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $275.60M derived: sum of 2 quarters · filed 2022-02-23 | $403.10M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $50.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $177.60M 10-Q · filed 2020-10-28 | ||
| 2019-06-30 | $127.50M 10-Q · filed 2020-07-31 | |||
| 2018-12-31 | $27.00M 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |